| 王 礼,吴月兵,余伟江.酪氨酸激酶抑制剂与化疗交替联合治疗晚期肺腺癌的临床疗效[J].肿瘤学杂志,2014,20(6):464-467. |
| 酪氨酸激酶抑制剂与化疗交替联合治疗晚期肺腺癌的临床疗效 |
| The Effect of Tyrosine Kinase Inhibitors Alternately Combined with Chemotherapy in the Treatment for Advanced Lung Adenocarcinoma |
| 投稿时间：2014-01-02 |
| DOI：10.11735/j.issn.1671-170X.2014.06.B006 |
|
 |
| 中文关键词: 肺肿瘤 酪氨酸激酶抑制剂 化疗 |
| 英文关键词:lung neoplasms tyrosine kinase inhibitor chemotherapy |
| 基金项目:武汉市重点攻关计划（201161038347） |
|
| 摘要点击次数: 1927 |
| 全文下载次数: 980 |
| 中文摘要: |
| 摘 要：［目的］ 探讨酪氨酸激酶抑制剂（TKI）与化疗异时联合治疗晚期肺腺癌患者的疗效和不良反应。［方法］收集66例晚期肺腺癌患者，应用含铂2药化疗，疾病进展时予TKI吉非替尼或厄罗替尼治疗，或TKI初始治疗进展后使用化疗；交替进行。总生存时间及不良反应为主要观察指标。［结果］ 66例患者中，58例是化疗—TKI治疗模式，再化疗的有效率为15.5%，8例是TKI—化疗模式，再次TKI的有效率为25.0%，稍高于化疗—化疗模式患者中第二次治疗的有效率（12.7%）（χ2=2.6，P=0.08）。化疗—TKI治疗与TKI—化疗患者的中位总体生存期(OS)无明显差异（18.3个月 vs 17.5个月）（P=0.44），但明显长于化疗—化疗患者（6.9个月）（P=0.0001）。交替治疗患者的3~4度不良反应与对照人群相似。［结论］ 晚期肺腺癌患者TKI与化疗交替联合治疗能提高有效率，明显延长生存时间，与交替方式（给药顺序）无关。 |
| 英文摘要: |
| Abstract：［Purpose］ To investigate the efficacy and adverse reactions of TKI metachronously alternately combined with chemotherapy in patients with advanced lung adenocarcinoma. ［Methods］ A total of 66 patients with advanced lung adenocarcinoma patients treated with two-drug chemotherapy platinum-contained，and tyrosine kinase inhibitors(TKI) gefitinib or erlotinib，or TKI and chemotherapy alternately with disease progression after TKI initially. Thirty-one patients with lung adenocarcinoma were as control. The primary endpoints of the study were overall survival and adverse reactions.［Results］ Of 66 patients，58 cases were chemotherapy-TKI treatment mode，and response rate of second chemotherapy was 15.5%. Eight cases with TKI-chemotherapy mode again，the TKI response rate was 25.0%. The median overall survival (OS) was not significantly different between chemotherapy-TKI therapy and TKI-chemotherapy(18.3 months vs 17.5 months，P=0.44)；but significantly longer than that of the control adenocarcinoma population without TKI (6.9 months，P=0.0001). Side effects of grade 3~4 in alternately treated patients were similar to control subjects. ［Conclusion］ TKI alternately combined with chemotherapy is able to improve prognosis significantly，which does not relate to treatment modalities (sequence of administration) in patients with advanced lung adenocarcinoma. |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |